None listed
Conditions
Brief summary
Studies have shown that medicinal cannabis can reduce chronic pain, neuropathic pain, cancer pain, chemotherapy-induced nausea, spasticity in Multiple Sclerosis, and epileptic seizures in patients. However, the true gauge and extent of how medicinal cannabis affects patients in real-life conditions is not fully understood. To gain a better understanding of the real-life impact of medicinal cannabis, the QUEST study (ACTRN12621000063819) assessed the impact of medicinal cannabis on patients’ quality of life, symptoms, and function. This study, named the Global Quest Initiative, aims to expand on the work done by QUEST, with an additional focus on health economics. Who is it for? You may be eligible to join this study if you are aged 18 years or older, have been identified as eligible to receive medicinal cannabis, have not started any prescribed medicinal cannabis therapy in the previous 4 weeks, or have commenced medicinal cannabis no more than 2 days ago. Study details All participants will be asked to complete a number of questionnaires at the time of commencing medicinal cannabis, and every 1-2 months over a period of 1 year, to measure quality of life, health service use, prescribed medication use, anxiety and depression, fatigue, sleep, pain, work performance, and motor function, depending on the participant’s health indication. The questionnaires will take approximately 1 hour to complete, and will be accessed online via a link emailed to participants. Participants will not receive any treatments or have their treatment altered as part of this study. It is hoped that this study will show that medicinal cannabis improves quality of life, symptoms, and function in chronic pain sufferers and other patients, and is cost-effective for the treatment of these conditions.
Interventions
This research will evaluate health economic relevant outcomes and patient-reported outcomes in patients with chronic conditions, who are being prescribed medicinal cannabis under the Special Access Scheme across clinics within Australia.
Patients will be assessed at baseline and every 1-2 months over a period of one year, using validated questionnaires to measure quality of life, anxiety and depression, fatigue, sleep, pain, work performance, and motor function, depending on the patient's heal
This research will evaluate health economic relevant outcomes and patient-reported outcomes in patients with chronic conditions, who are being prescribed medicinal cannabis under the Special Access Scheme across clinics within Australia. Patients will be assessed at baseline and every 1-2 months over a period of one year, using validated questionnaires to measure quality of life, anxiety and depression, fatigue, sleep, pain, work performance, and motor function, depending on the patient's health indication. The validated questionnaires we will use include EQ-5D, DASS21, HPQ-AP, and Health Service Utilisation (HERU). Each questionnaire should take less than 15 minutes to answer and participants will self-complete questionnaires through an online platform at home, accessible on a computer or other device with internet connection. Surveys will be completed at baseline before starting medicinal cannabis, at 2-3 weeks (end of titration period), and then at 1-, 3-, 6-, 9-, and 12-months post-titration period, and then at six month periods for the duration of a participant’s involvement with the study.
Sponsors
Little Green Pharma Ltd
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All of the following must be satisfied for enrollment in the study: • adult patients (aged 18 years) • patient has been identified as eligible to receive medicinal cannabis by a TGA approved Authorised Prescriber or via the Special Access Scheme (SAS-B) and the doctor has sought and obtained TGA approval for Little Green Pharma (LGP) products for their patient. • patient is able to read and understand English • patient is able to provide informed consent • patient has not started any prescribed medicinal cannabis therapy in the previous 4 weeks; or started prescribed LGP medicinal cannabis therapy within the previous 2 days (we expect no therapeutic benefit within 2 days) and has not received any prescribed medicinal cannabis therapy in the previous 4 weeks • patient has a life expectancy of more than 3 months .
Exclusion criteria
Patients will be excluded from the study if any of the following criteria apply: • are unconscious or confused • have cognitive impairment • are pregnant or breastfeeding • are unable to speak, read and/or write in English • are denied access to medicinal cannabis under the relevant Special Access Scheme (SAS) for their country of registration • are unable to provide informed consent • are already receiving prescribed medicinal cannabis treatment for more than 2 days • have received prescription medicinal cannabis within the last 4 weeks (excluding previous 2 days)
Outcome results
None listed